News for Mereo BioPharma Group plc (MREO)

We recently published a list of the 13 Best Biotech Penny Stocks to Buy According to Hedge Funds. In this article, we are going to take a look at where Mereo BioPharma Group (NASDAQ:MREO) stands against other biotech penny stocks. Peter Marks’s departure from the FDA has left innovators concerned regarding the current state of […]

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

MEREO BIOPHARMA (MREO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Stocks Analysis by MarketBeat.com (Jeffrey Neal Johnson) covering: Ford Motor Company, Goodyear Tire & Rubber Co, Nokia Corp ADR, Mereo BioPharma Group PLC ADR. Read MarketBeat.com (Jeffrey Neal Johnson)'s latest article on Investing.com

LONDON, March 05, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc ( MREO) (”œMereo” or the ”œCompany”), a clinical-stage biopharmaceutical company fo

Significant Transaction in Mereo BioPharma On December 31, 2024, ADAGE CAPITAL PARTNERS GP, L.L.C. (Trades, Portfolio) executed a notable transaction by acquiri

Mereo BioPharma shifts focus to rare diseases with setrusumab showing strong results for Osteogenesis Imperfecta. Learn more on MREO stock here.

Mereo BioPharma Provides Update on Lead Clinical Programs

LONDON, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Mereo BioPharma Group plc ( MREO) (”œMereo” or the ”œCompany”), a clinical-stage biopharmaceutical company foc

Mereo BioPharma to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

U.S. stocks traded mostly higher midway through trading, with the S&P 500 gaining around 0.4% on Monday. The Dow traded down 0.08% to 43,794.43 while the NASDA...

Mereo BioPharma (MREO) stock climbed 7% after Jefferies initiated coverage with a buy rating, citing the company’s drug candidates setrusumab and alvelestat. Read more here.

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please ...

Mereo BioPharma targets osteogenesis imperfecta market growth with setrusumab. Discover why MREO stock is well-positioned for gains with positive trial results.

NOVATO, Calif., Sept. 26, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that it will present seven abstracts...

Mereo BioPharma's chief scientific officer sells shares worth over $69,000

Mereo BioPharma's general counsel sells over $133k in company stock

Mereo BioPharma to Participate in Fireside Chat at the 2024 Cantor Global Healthcare Conference